You may or may not have heard Treat NMD has scheduled a meeting with EMEA (European Medicines Agency) or the regulatory agency for the EU. The purpose of the meeting is dialogue: discussion about potentially promising treatments for Duchenne. The discussion will cover a range of areas to include drug development, clinical trials, and outcome measures. Our champions in Congress have written to FDA, urging them to take part in this critically important conversation.
For the last many… Continue